Local tolerability of topically applied methylprednisolone aceponate.
Schering AG, Human Pharmacology, Berlin, Germany.
A
A
Kecskés
P
P
Jahn
L
L
Lange
D000279:Administration, Cutaneous; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001284:Atrophy; D001624:Betamethasone Valerate / Q000008:administration & dosage / Q000494:pharmacology; D002990:Clobetasol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D017484:Dermatitis, Phototoxic / Q000209:etiology; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007509:Irritants; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D009779:Occlusive Dressings; D009824:Ointments; D011239:Prednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D012882:Skin Tests
D000893:Anti-Inflammatory Agents; D007509:Irritants; D009824:Ointments; D001624:Betamethasone Valerate; D011239:Prednisolone; D002990:Clobetasol; C078007:methylprednisolone aceponate; C035287:prednicarbate; D008775:Methylprednisolone